{
    "nct_id": "NCT03685708",
    "official_title": "Response to the HEPLISAV-B Hepatitis B Vaccine in Treatment Naive Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's -Tyrosine Kinase Inhibitor (BTK-I)",
    "inclusion_criteria": "* INCLUSION CRITERIA:\n* Diagnosis of CLL/SLL which is made according to the updated criteria of the NCI Working Group.\n* No known active or past hepatitis B infection\n* No history of prior hepatitis B virus vaccination (approved or investigational)\n* History of negative hepatitis B viral titers (negative HBsAg, HBsAb and HBcAb)\n* Cohort 1: Treatment naive CLL patients\n* Cohort 2: Subjects must be receiving ibrutinib monotherapy for at least 6 months prior to administration of the first vaccine dose\n* Cohort 3: Subjects must be receiving acalabrutinib monotherapy for at least 6 months prior to administration of the first vaccine dose\n* Age greater than or equal to 18 years.\n* ECOG performance status of 0-1\n* Able to comprehend the investigational nature of the protocol and provide informed consent.\n\nEXCLUSION CRITERIA:\n\n* Female patients who are currently pregnant.\n* Any uncontrolled active systemic infection\n* Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator s opinion, could compromise the subject s safety or put the study outcomes at undue risk\n* History of severe allergic reaction to any component of HEPLISAV-B, including yeast\n* Receive intravenous or subcutaneous immunoglobulin (IVIG) within 3 months prior to vaccination\n* Concomitant use of immunosuppressive agents (e.g. steroids, radiotherapy, chemotherapy)\n* Hereditary or acquired immunodeficiency syndrome unrelated to CLL\n* Non-English speaking individuals will be excluded from the study\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 99 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}